Skip to main content

Chronic Kidney Disease (CKD)

Nephrology
4
Pipeline Programs
8
Companies
6
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

On Market (1)

Approved therapies currently available

AbbVie
ZEMPLARApproved
paricalcitol
AbbVie
Vitamin D2 Analog [EPC]intravenous1998

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
1
ParicalcitolPhase 31 trial
Active Trials
NCT04064827Terminated2Est. Jun 2025
Pfizer
PfizerNEW YORK, NY
1 program
1
Epoetin Hospira ArmPhase 31 trial
Active Trials
NCT02504294Completed432Est. Jul 2016
Sandoz
SandozAustria - Kundl
1 program
1
LHW090Phase 21 trial
Active Trials
NCT02678000Completed84Est. Oct 2018
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Chronic Kidney DiseaseN/A1 trial
Active Trials
NCT07391904Enrolling By Invitation255Est. Feb 2027
Astellas
AstellasChina - Shenyang
1 program
Non-interventionalN/A1 trial
Active Trials
NCT04042350Completed2,773Est. Feb 2020
Regeneron
RegeneronTARRYTOWN, NY
1 program
NoninterventionalN/A1 trial
Active Trials
NCT05106387Recruiting20Est. Feb 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AbbVieParicalcitol
PfizerEpoetin Hospira Arm
SandozLHW090
Angeles TherapeuticsChronic Kidney Disease
RegeneronNoninterventional
AstellasNon-interventional

Clinical Trials (6)

Total enrollment: 3,566 patients across 6 trials

NCT04064827AbbVieParicalcitol

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Start: Sep 2020Est. completion: Jun 20252 patients
Phase 3Terminated
NCT02504294PfizerEpoetin Hospira Arm

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Start: Jul 2015Est. completion: Jul 2016432 patients
Phase 3Completed

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

Start: Mar 2017Est. completion: Oct 201884 patients
Phase 2Completed
NCT07391904Angeles TherapeuticsChronic Kidney Disease

Patient-centered Precision Medicine Lab Result Communication for Older Adults

Start: Mar 2026Est. completion: Feb 2027255 patients
N/AEnrolling By Invitation
NCT05106387RegeneronNoninterventional

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Start: Oct 2023Est. completion: Feb 202820 patients
N/ARecruiting
NCT04042350AstellasNon-interventional

Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis

Start: May 2019Est. completion: Feb 20202,773 patients
N/ACompleted

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,566 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.